pyridinolcarbamate has been researched along with Psoriasis in 1 studies
Pyridinolcarbamate: A drug that has been given by mouth in the treatment of atherosclerosis and other vascular disorders, hyperlipidemias, and thrombo-embolic disorders. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1408)
Psoriasis: A common genetically determined, chronic, inflammatory skin disease characterized by rounded erythematous, dry, scaling patches. The lesions have a predilection for nails, scalp, genitalia, extensor surfaces, and the lumbosacral region. Accelerated epidermopoiesis is considered to be the fundamental pathologic feature in psoriasis.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Rakhmatov, AB | 1 |
| Bilash, NV | 1 |
1 other study available for pyridinolcarbamate and Psoriasis
| Article | Year |
|---|---|
[Effect of complamin and prodectin on microcirculation and lipid metabolism in psoriasis patients].
Topics: Adolescent; Adult; Carbamates; Conjunctiva; Female; Humans; Lipoproteins; Male; Microcirculation; Mi | 1983 |